Korean Universities Develop Novel KE-VAC Vaccine Platform

SEOUL, South Korea (April 9, 2025) — Researchers ‌from‍ Chungnam National University, the Korea Virus Basic Research Institute, and⁣ Sungkyunkwan University have ⁣jointly announced the development of a next-generation vaccine platform ⁣called KE-VAC (Kinetically Engineered Vaccine). This innovative platform ​is designed ⁢to stimulate the immune system in a manner ⁢similar⁤ to natural infections,perhaps leading to a ⁤more robust and long-lasting immune response against a ​variety of viruses and their variants.

KE-VAC: Mimicking Natural Infection for Enhanced Immunity

The ​findings of this collaborative⁤ research ‍effort were​ published online March 25⁣ in Nature Communications, a peer-reviewed scientific journal.

Key researchers ‍involved in the⁤ study include Professor lee Jong-soo from Chungnam National University’s ⁣Veterinary College, with DK Haluwana listed as co-first author; Professor​ Yong-taek Team from Sungkyunkwan University; and ‍the ‍director of the Korea Basic‌ Research Institute.

How KE-VAC Works

The KE-VAC platform utilizes nanoparticles ⁤to‍ control ‌the toll-receptor 7/8 agonist (TLR7/8‍ agonist), ⁢mimicking viral genetic material to⁢ gradually activate cells. This approach ‌is coupled with aluminum-based ⁣adjuvants that slowly release antigens. The combined⁣ effect‍ ensures that the antigen ⁢and‍ immune reinforcements work synergistically,addressing the limitations⁢ of existing vaccines,such as short-term ⁣immune sustainability ⁣and​ immune‍ cell fatigue.

Preclinical Testing Shows Promise

In preclinical trials, the research team tested KE-VAC ⁢in mice and ferret⁤ models‍ to assess its⁣ effectiveness against various pathogens, ⁤including variants of the virus that causes COVID-19, influenza viruses, and the severe fever ⁣with thrombocytopenia syndrome ⁤(SFTS) virus. The results indicated a ⁤specific cytoplasmic immune response, suggesting broad applicability.

Potential Impact on ⁣Public health

Researchers believe that ⁢KE-VAC’s immune-stimulating mechanism represents ‌an advancement over ⁢existing⁢ mRNA ‍vaccines and aluminum-based vaccines.‌ They anticipate that this ​new platform ⁤could substantially contribute to⁣ infectious disease prevention and public health by‍ offering a⁣ novel⁢ approach to vaccine technology. Future‌ clinical trials are planned to‍ evaluate the​ potential for human ​application.

Researcher’s Viewpoint

According to Professor Lee Jong-soo of⁢ Chungnam⁤ National University, KE-VAC ​creates ​”a more flexible and strong immune system through a multi-dimensional stimulus that ⁤mimics natural infections beyond the limitations of existing vaccines⁢ focused on short-term immunity.”

Funding

The research received support from the Support Project of the⁤ Basic⁤ Science⁤ Research Institute, the‍ Korea Research Foundation’s mid-sized researcher support‍ project, and the university-focused‍ research⁣ institute support ⁢project.

KE-VAC Vaccine: ‌Your top Questions Answered

This article provides a comprehensive ​overview of KE-VAC (Kinetically Engineered Vaccine),a novel vaccine platform developed by researchers from Korean universities.It⁢ aims to mimic natural infections, offering a potentially more robust and‍ long-lasting immune response. Here’s a breakdown of the key aspects:

What is ‍KE-VAC and How Does It Work?

KE-VAC is a next-generation vaccine platform designed to stimulate the immune system in a way that resembles a natural infection. This innovative approach is intended to create a more potent and durable immune⁣ response. ⁢The platform⁣ works by:

• Using nanoparticles to control a TLR7/8 agonist.
• Mimicking viral genetic material to ‍stimulate cell activation gradually.
• Combining this with aluminum-based adjuvants to slowly release antigens.

This synergistic approach aims to overcome the limitations of existing vaccines, such as short-term immunity and immune cell fatigue. The⁣ goal is to provide a more flexible and stronger immune ⁤system.

What are the Key Benefits of KE-VAC?

KE-VAC offers several potential advantages over existing vaccine technologies:

• Enhanced Immunity: Mimics natural infections ⁢for a potentially more robust and long-lasting immune response.
• Addresses Limitations of Existing Vaccines: Aims to overcome issues like short-term immunity and immune cell fatigue.
• Broad Applicability: Preclinical trials suggest effectiveness against various pathogens, including variants of COVID-19, ‍influenza viruses, and SFTS virus.

Who Developed the KE-VAC Vaccine Platform?

The KE-VAC platform was developed through a collaborative effort‌ by researchers from:

• Chungnam National University ⁤(Professor Lee Jong-soo)
• Sungkyunkwan University (Professor Yong-taek Team)
• Korea Basic Research Institute (Director)

What‍ Pathogens Has KE-VAC Been Tested Against?

Preclinical trials have tested KE-VAC’s effectiveness against the following:

• Variants⁤ of the virus that causes COVID-19
• Influenza viruses
• Severe fever with thrombocytopenia syndrome (SFTS) virus

What are the Potential Implications ‌for Public Health?

Researchers believe KE-VAC represents an advancement over existing vaccine technologies like ‍mRNA‌ and ‍aluminum-based vaccines. It is hoped that KE-VAC could considerably contribute⁤ to:

• Infectious disease prevention
• Public health improvements

How Does KE-VAC Compare to Existing Vaccines?

The ⁢following table provides a comparison of KE-VAC to other vaccine⁣ types based⁣ on facts in the source article:

Feature	KE-VAC	Existing mRNA Vaccines	Aluminum-based Vaccines
Mechanism	Mimics natural infection; uses nanoparticles and TLR7/8 agonist; slow-release antigens	Not explicitly mentioned​ in source	uses aluminum adjuvants to ​slowly release antigens.
goal	More robust and long-lasting immunity	Not explicitly mentioned in source	Not⁢ explicitly mentioned in ​source
Key Benefit(s)	Addresses limitations of existing vaccines	Not ⁤explicitly mentioned in source	Not explicitly mentioned in source

When Will KE-VAC Be Available for Human​ Use?

Future clinical trials are planned to evaluate the​ potential‍ for human request. ⁣The timing of availability⁤ is not specified in the ⁢source material.

Is KE-VAC Suitable⁢ for Children?

The provided article does not specify the suitability ‌of KE-VAC for children. Further research and clinical trials are necessary to determine its safety and efficacy for different age groups.

Where did the Funding‌ for this Research Come From?

The research received funding from:

• Support Project of the Basic Science Research Institute
• Korea Research Foundation’s mid-sized ‍researcher support project
• University-focused research institute support project